drugset / Trial / NCT05385575
A Study to Evaluate Effects of KN056 in Healthy Participants
RandomizedSequentialDouble-blindTreatment
Summary
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN056 in healthy participants.
Timeline
- Start
- 2022-08-09
- Primary completion
- 2023-12-22
- Completion
- 2024-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN056 | Protein / enzyme biologic | 0.1 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 0.3 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 3 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 12 mg | Subcutaneous |
| Subject | KN056 | Protein / enzyme biologic | 18 mg | Subcutaneous |